Eyelid pressure patching enhances amniotic membrane therapy for corneal healing
Combining decellularized amniotic membrane basement membrane (AMBM) (Biovance® 3L Ocular, Verséa Ophthalmics) with eyelid pressure patching is a safe and effective treatment for persistent corneal epithelial defects (PCEDs), leading to complete healing in most cases without complications, according to a study.
In this retrospective study, researchers analyzed 144 eyes treated with either a single-layer or 3-layer AMBM and a 24-hour eyelid pressure patch. Among patients receiving single-layer AMBM, all achieved complete healing with full membrane dissolution. In the 3-layer group, although all cases showed improved corneal staining, 20–30% of the membrane remained undissolved. No patients experienced pain, discomfort, or infection.
This study highlights the effectiveness of using dehydrated, decellularized AMBM alongside eyelid pressure patching to treat PCEDs often caused by advanced dry eye disease and neurotrophic keratitis. The researchers concluded that amniotic membrane therapy supports healing by promoting epithelial cell growth, reducing inflammation and pain, and preventing scarring. It also acts as a protective barrier, maintaining tear film stability and preventing dryness.
Reference
Linsey K. Use of an Eyelid Pressure Patch Concomitantly with a Decellularized Dehydrated Amniotic Membrane for Ocular Surface Disease Management. Ophthalmol Ther. 2025;14(3):573-584. doi: 10.1007/s40123-025-01094-2. Epub 2025 Feb 3. PMID: 39899264; PMCID: PMC11825428.
